SPRB Spruce Biosciences Inc.

Biotech Analyst Ratings

Latest News

1. 11 May 2022 Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

   25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023

   Debt Facility with Silicon Valley Bank Amended to Provide Up to $10 Million Credit Line in 2022

   Tildacerfont Patent Portfolio Estate Expanded with Key Method of Use Patents

   Libbie Mansell, Ph.D., M.B.A., R.A.C., Appointed Chief Regulatory and Quality Officer

   Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates.

   "Throughout the first quarter of 2022, we continued to drive our…

   View Full Article
2. 03 May 2022 Spruce Biosciences to Participate in May Investor Conferences

   Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.

   • RBC Capital Markets Global Healthcare Conference
     Date: May 17-18, 2022
     Format: Fireside chat (May 17 at 10:00 a.m. ET) and 1x1 meetings

   • H.C. Wainwright Global Investment Conference
     Date: May 23-26, 2022
     Format: Company presentation (May 25 at 4:00 p.m. ET) and 1x1 meetings

   Interested parties can access the webcast for each conference presentation from the Events section of the company's investor relations website at https://investors.sprucebiosciences.com…

   View Full Article
3. 11 April 2022 Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer

   Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company's global regulatory affairs and quality strategy.

   "Dr. Mansell brings extensive regulatory affairs and quality expertise at precisely the right time for Spruce, as we progress tildacerfont through clinical development for adults and children with classic congenital adrenal hyperplasia and women with polycystic ovary syndrome," said Javier Szwarcberg, M.D., M.P.H., Chief…

   View Full Article
4. 14 March 2022 Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

   Topline Safety Data from Cohort 1 of Phase 2 Pediatric Classic CAH Study Expected by 1H 2023

   Will Charlton, M.D., M.A.S., Appointed Chief Medical Officer

   Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

   "Over the last quarter, we have made notable progress in our efforts to advance new treatment options for people living with rare endocrine disorders and to maximize the potential of tildacerfont as a therapeutic to treat people living with classic congenital adrenal…

   View Full Article
5. 14 March 2022 Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer

   Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Will Charlton, M.D., M.A.S., has been appointed Chief Medical Officer, and will succeed Rosh Dias, M.D., who has stepped down to pursue other opportunities. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of clinical research experience in industry and academia and will lead the company's clinical development and global drug development strategy.

   "We are pleased to welcome Will as our Chief Medical Officer, and we look forward to his leadership and guidance as we continue to advance our pipeline…

   View Full Article